STOCKS TELEGRAPH

Tag: Inc.

  • Summit Wireless Technologies, Inc. (WISA) stock is Popping High today: Why is it so?

    Summit Wireless Technologies, Inc. (WISA) stock announced the launch of its custom Amazon storefront after which the stock price saw a push of  40.79% to reach $5.73 a share as of this writing. The momentum was already created in the previous trading session as WISA stock went high by 16.95% at closing. Let’s deep dive to explore more of it.

    What’s Happening?

    Summit Wireless Technologies, Inc. is engaged in the developing, manufacturing, and selling of integrated circuits for home entertainment as well as the audio market in the United States and many other countries across the globe. The stock announced the launching of its Amazon Storefront through which it would sell its all-certified products. The customer experience would be strengthened as the WISA products would be purchased easily from one page.

    WiSA’s Amazon storefront will play a major role in the continued growth of the global wireless WiSA Certification category that includes wireless transmitters, TVs and WiSA surround sound configurations in which Dolby Atmos is also included.

    WiSA Wave Marketing Program:

    WISA stock is expecting 2 million visitors to its website due to the success of its efficient WiSA Wave  Marketing Program. The team is working closely with consumer electronic members in order to create a successful dedicated online store. The wave marketing campaign is focused on educating the benefits of WiSA to its target audience. The wave initiatives also emphasizing the benefits of home cinema experiences that member brands are delivering to their consumers.

    WiSA SoundSend Certified Program:

    Yesterday on July 21, 2021, WISA stock did announce that it has launched its WiSA SoundSend Certified Program. The purpose of this initiative by the WISA stock is to work with TV manufacturers in order to make a simple and flawless connection and interoperability with the WiSA SoundSend wireless audio transmitter along with Toshiba TV “REGZA”.This will be the first TV brand that will deliver solutions with the new certifications.

    After passing the successful test to work perfectly with SoundSend, Smart TVs will then get the WiSA SoundSend certified status. The test will include all the audio connections as well as control requirements between Smart TV and SoundSend.

    Conclusion:

    Things are going well for WISA stock as far as market sentiment is concerned. The Amazon StoreFront and WiSA SoundSend Certified program would significantly help in the growth of the stock.

  • Creatd, Inc. (CRTD) stock is falling today: Why is it so?

    Creatd, Inc. (CRTD) stock is falling today: Why is it so?

    Creatd, Inc. (CRTD) stock announced the pricing of a public offering of its common stock after which the CRTD stock happened to be red and stock price saw a downtrend of 15.74% a share as of this writing. The stock went high in the previous trading session and closed with a 4.03% gain. Let’s discuss more about the CRTD stock.

    What’s Happening?

    The announcement of a public offering by the Creatd stock is the main culprit behind the falling CRTD stock price. According to the public offering, 750,000 shares of the CRTD’s common stock would be offered at a per-share price of $3.40 which means that the offering would produce roughly$2.6 million in total. Creatd stock might sell 15% or 112,500 additional shares of its common stock via granting the 30-day option to underwriters. After meeting the customary closing conditions, the offering would expect to end on June 21, 2021. The net proceeds are estimated to be approximately $2.4 million after the deduction of underwriting discounts and commissions. The net proceeds would be used for general corporate purposes by the CRTD stock.

    Creatd, Inc to acquire 55% WHE Agency:

    Yesterday on June 16, 2021, CRTD stock did announce that it has signed the memorandum of understanding via its wholly owned subsidiary Creatd Partners for the acquisition of a 55% ownership stake in the WHE agency. $275,000 in cash $660,000 in stock was specified for this proposed transaction. Creatd stock intends to carry out the definitive agreements in the early phase of the third quarter of 2021.

    The memorandum has expanded the corporate strategy of the Creatd stock via the expansion of its tools and resources for creators. According to the management, the acquisition will benefit both companies in terms of revenues, and WHE is expected to contribute more than $1 million in agency-related net revenue in the next year.

    Launch of ‘Fiction’, a Vocal Community:

    About a week ago, Creatd stock made an announcement of launching the new ‘Fiction’ community on vocals.The purpose of this launch is to showcase the imaginative work of creators. Furthermore, the CRTD stock also announced the world’s first crowdfunding book publisher, Unbound as its official supporter of the Fiction community.

    Conclusion:

    The announcement of public offering is the obvious reason for the falling CTRD stock price. Such rises and falls don’t affect the long-term investors who mainly eye on the stock’s fundamentals, balance sheet, and future developments.

  • Why Inovio Pharmaceuticals, Inc. (INO) stock is rising in the Pre-Market today?

    Why Inovio Pharmaceuticals, Inc. (INO) stock is rising in the Pre-Market today?

    Shares of Inovio Pharmaceuticals, Inc. (INO) stock were rising in the pre-market trading session today after dropping as much as 30% during the last trading session. INO price saw a push of  0.58% to reach $6.89 a share at the time of this writing. INO dropped by 24.97% at the previous closing with a $6.85 per share price. Let’s see the reason behind this bull.

    What’s happening?

    Today’s bullish sentiment has nothing to do with any good news related to INO stock. There are no signs of analyst upgrades or increased targeted per share price of the INO to justify the rising behavior of INO stock. However, INO stock faced a massive drop of 30% during the last trading session after the announcement on Friday, April 23, 2021, that it’s funding for late-stage study testing of COVID-19 vaccine candidate has been stopped by the U.S  government due to the excessive availability of authorized vaccine in the country. However, funding for the ongoing mid-stage study testing will continue for the vaccine candidate of INO by the U.S government.

    The stopping of the fund for the late-stage study testing of a COVID-19 vaccine candidate resulted from the changing environment of COVID-19 amid the rapid development of vaccines and does not reflect the awardee or product. Moreover, this decision is also not a reflection of any data released for the INO-4800 vaccine. INO stock will continue to perform other operations with the U.S. government without any effect.

    Inovio is planning for a late-stage global study with its global collaborators INOVIO’s China partner, Advaccine, and the International Vaccine Institute (IVI,) based on the upcoming results related to safety and immunogenicity from mid-stage trial.

    Inovio Pharmaceuticals, Inc:

    Inovio Pharmaceuticals, Inc is a biotechnology company focused on the treatment of human papillomavirus (HPV) related diseases via the development of DNA medicines. INO stock has also been working on the development and commercialization of medicines to treat cancer and various infectious diseases. INO stock having a market cap of 1.908B was founded in 1979  and its headquarters is in Plymouth Meeting, Pennsylvania.

    Conclusion:

    The INO stock price is rising in the stock market today despite the absence of any good news related to it.INO stock experienced a massive drop in the previous trading session. Sometimes investors take it as the opportunity to purchase shares of a particular stock at a lower price considering the long-term benefits. In short deep fundamental and technical analysis is necessary before adding INO stock to the portfolio.

  • Farmmi, Inc. (FAMI) stock fell in the Tuesday aftermarket: Why did it happen?

    Shares of the Farmmi, Inc. (FAMI) stock continued the downtrend in the after-market trading session.FAMI stock price saw a downtrend of 9.77% to drop at 0.85 a share in the late hours of Tuesday, April 20, 2021. FAMI was gloomy in the previous trading session and dropped by 6.73% at closing. Let’s try to find the reason behind this fall.

    What’s happening?

    There is no new story since April 16, 2021, related to the FAMI stock to justify the current bearish sentiment. No analysts downgrade or shrank targeted per share price of FAMI stock has been reported recently. Such falls or rises in the stock market spread curiosity among the individuals as they always try to find the reason to calm themselves.

    Recent Development of FAMI stock:

    On April 16, 2021, FAMI  stock did the announcement of winning the multi-product order for export to the U.S. by its subsidiary Zhejiang Forest Food Co., Ltd. The order is related to the flavored dried whole and sliced mushrooms, and dried black fungus which are high-quality products of Farmmi stock. The customer is a well-established trading company that is supplying food products to major global hotel and supermarket chains. STANFORD hotel chain and the H-MART supermarket chain are the names of the favorite among them. This order would continue the sales momentum for the FAMI stock. Previously on April 08, 2021, Zhejiang received the multi-product order for dried whole and sliced Shiitake mushrooms, and black fungus from Israel.

    On April 13, 2021, FAMI stock announced the closing of an over-allotment option pursuant to which selling of which 970,419 ordinary shares happened at $1.15 per ordinary share price. The gross proceeds from this option as well as from previously closed underwritten public offering were totaled approximately $8.6 million without the deduction of underwriting discounts, commissions, and other related expenses of Farmmi stock.

    Conclusion:

    FAMI stock was gloomy in the aftermarket as well as the previous trading session. This fall is not attributed to any recent news related to Farmmi Inc. however its recent developments show that Farmmi is continuing the momentum of its agricultural products. In a nutshell, investors need to do both fundamental and technical analysis before adding this stock to their portfolio.

  • Netflix, Inc. (NFLX) stock falls in the Tuesday aftermarket: Why is it so?

    Netflix, Inc. (NFLX) stock falls in the Tuesday aftermarket: Why is it so?

    Shares of Netflix, Inc. (NFLX) stock continued to fall in the after-market session yesterday after facing the downtrend of 0.88% at the previous closing. NFLX price faced a downtrend of 8.76% to drop at $501.44 a share in the late hours of Tuesday, April 20, 2021. This fall is attributed to the recently announced first-quarter results by NFLX stock in which Netflix subscriber growth sharply decreased. Let’s discuss the recent results in detail.

    NFLX stock earnings and revenues:

    NFLX stock posted $3.75 earnings per share in the first quarter of 2021 as compared to $1.57 earnings per share in the same quarter of the previous year. The Zacks Consensus estimate for the NFLX was $2.98 earnings per share.NFLX stock has beaten the Zack Consensus estimate of revenue by 0.39% and generated $7.16 billion revenue in the first quarter of 2021 as compared to $5.77 billion in the same tenure of the previous year.Net income of NFLX rose to $1.71 billion from$709 million as compared to the first quarter of 2020.

    NFLX stock sharply decreased the Subscriber Growth:

    Netflix stock subscribers’ growth decreased sharply in the first quarter of 2021 as it just added 3.98 million subscribers in its database which is very much less as compared to 15.8 million new paying users in the same quarter of the prior year. The first three-month new subscriber number is also less than the NFLX’s own guidance of 6 million from January.

    Why subscriber’s growth decreased?

    Management thinks that the decreased subscriber’s growth is attributed to COVID-19 which greatly hit the production of T.V shows, and movies thus slowed down the production process. The projected number of new subscribers for the second quarter is just 1 million by NFLX stock while analysts had previously projected it to be nearly 4.8 million.

    Netflix plans:

    Management of Netflix is optimistic that its membership growth will again take the rising momentum in the second quarter as it is going to release the new seasons of  “You,” “Money Heist,” and “The Witcher” along with the action movie Red Notice,” and many others.

    Conclusion:

    It is obvious that shares of NFLX stock plunged due to decreased subscribers’ growth in the first three months of 2021. Moreover, Netflix is facing great competition as rival media companies are spending billions to compete with it. Management is optimistic that the NFLX stock would again get the rising momentum after releasing blockbuster movies and seasons in the second quarter of 2021. The consensus estimate of revenues for the second quarter is $7.37 billion and $30.01 billion for the fiscal year 2021. In a nutshell, good homework about NFLX stock is necessary for investors.

  • LifeMD, Inc. (LFMD) stock rises today: Why is it so?

    LifeMD, Inc. (LFMD) stock rises today: Why is it so?

    LifeMD, Inc. (LFMD), a telemedicine company, responded to the short report making false claims against today it after which the LFMD stock happened to be green as it saw a push of 0.22% to reach $9.02 a share at the time of this writing. In the previous trading session, LFMD stock went down due to the short-seller report issued by Culper Research and closed with a 23.99% drop. Let’s try to understand more of it.

    What’s happening?

    LifeMD denied the claims against it and its present and former officers by the Cupler Research firm. Culper Research alleged that LifeMD is misleading its shareholders by providing false information related to its doctors and health professional and even unlicensed professional are a part of it. Culper Research further claimed that the LFMD is engaged in fraudulent and illegal activities.LFMD completely denied these claims and its outside legal counsel Quinn Emanuel Urquhart & Sullivan, LLP has started the investigation of the source of these claims.LFMD will soon provide a detailed public response against these false claims and will take appropriate legal action.

    Previous Development of LFMD stock:

    On April 07, 2021, LFMD stock did announce the launching of NavaMD™ which is LifeMD’s personalize teledermatology brand and clinic. The clinic offers services to patients across 50 states. This was the third launch of the brand by the LFMD stock within years. NavaMD would entertain patients seeking dermatology services which include skin conditions like acne, rosacea, hyperpigmentation, signs of aging, and many more.

    Financial View of LFMD stock:

    On March 29, 2021, LFMD stock announced its fourth quarter and full-year 2020 financial results in which LFMD stock generated $12.9 million revenue in the fourth quarter of 2020 representing a huge increase of 227% as compared to the same period of the prior year. Full-year revenue for 2020 surged by 199% to reach $37.3 million as compared to the revenue of the previous year. Gross profit for the fourth quarter and full year was $8.9 million and $28.4 million, respectively.

    Conclusion:

    LFMD stock got crushed in the previous trading session due to false claims by the Culper Research Firm but happened to be green after the announcement of its response against the claims. The yearly revenue of the LFMD stock showed growth due to the increasing demand for telehealth services over the year. LifeMD will provide a detailed public response soon which would further clear the confusion of individuals.

  • Why 9 Meters Biopharma, Inc. (NMTR) stock decreased in pre-market?

    9 Meters Biopharma, Inc. (NMTR) stock increased 3.03% closing at $1.36 compared to the previous day closing of $1.32 but in the premarket, the NMTR stock decreased by 15.44% to $1.15. NMTR announced that it has initiated a proposed underwritten public offering of its shares of common stock on March 30th, 2021.

    Overview of 9 Meters Biopharma, Inc.

    9 Meters Biopharma Inc. is a biotech company that focuses on rare and unmet needs of gastroenterology. NMTR is headquartered in the Research Triangle, East Coast, Southern United States. NMTR is advancing itself towards a phase-2 trial for the drug candidates for non-responsive celiac disease, an immune disease, and a phase 3 trial for short bowel syndrome, a rare orphan disease. NMTR is backed by over 150 patents worldwide and owns all the global rights to their products. NMTR has a strong management team that has a history of bringing novel therapeutics to the market.

    NMTR proposed a public offering of common stock

    On Tuesday, 30th March 2021, 9 Meters announced that it has initiated a proposed underwritten public offering of its shares of common stock. It is expected that NMTR will grant underwriters a 30-day option to purchase the additional 15% common stock shares that will be sold during the public offering. NMTR itself will sell all the shares in the proposed offering. There is no assurance that the offering will be completed and it is subject to the market and other conditions. The joint book-running managers for the proposed offering are William Blair & Company, LLC and Citigroup. NMTR announced that it will be offering 30,000,000 shares of its common stock to the public at a price of $1 per share. It is expected that the offering will close at 5th of April. The gross proceeds of NMTR from the public offering are expected to be $30 million, prior to the deduction of offering expenses payables, underwriting discounts, and commissions. An initial prospectus related to the proposed offering of NMTR will be filed with the Securities and Exchange Commission (SEC) and will later be available on SEC’s website. The copies of the prospectus related to the offering will also be available to be obtained from Citigroup Global Markets Inc. The final report of the offering will be revealed in a final prospectus to be filed with the SEC.

  • Moleculin Biotech, Inc. (MBRX) stock is popping high today. What’s going on?

    Moleculin Biotech, Inc. (MBRX) stock is popping high today. What’s going on?

    Moleculin Biotech, Inc. (MBRX) received the approval of Fast Track Designation for Annamycin by the FDA after which the MBRX stock happened to be green today. MBRX stock price saw an uptrend of 21.08% to reach $4.48 a share as of this writing. The MBRX stock was down with a 3.39 drop at the previous closing. Let’s have a look at current scenarios.

    A Brief look at Approval:

    Moleculin Biotech is mainly working on the treatment of tumors and viruses via the development of oncology drug products. Moleculin stock recently announced that it has got approval for fast-track designation for Annamycin, an anthracycline antibiotic, by the U.S. Food and Drug Administration. In connection with this approval, MBRX will now be able to review Annamycin results against the treatment of soft tissue sarcoma (STS) lung metastases. There are good chances for Moleculin to approve its product against STS lung metastases as well as acute myeloid leukemia.

    Why Annamycin is better?

    Approximately 130000 cases of Soft tissue sarcomas are reported annually around the globe and most of them are handled through the surgical procedure. Analysis shows that 20 to 50% of these cases metastasize to the lungs and once it happens, it then becomes more difficult to treat such cases. So far treatment is very limited for this condition due to severe cardiotoxicity effects by previously approved drugs. Annamycin on the other hand proved to be much effective so far as it does not cause severe cardiotoxicity in patients and hence better than the former drugs.

    Financial View  of MBRX stock

    Recently announced earnings results of RMBX stock show that Moleculin research and development surged to $12.8 million in 2020 as compared to $11.0 million in 2019 due to increased clinical trials that increased the operational costs. General and administrative costs were recorded at $6.8 million in 2020 while these were $6.3 million in 2019. An increase in these costs is mainly due to an increase in the staff but thanks to the COVID-19 that overall travel expenses were significantly reduced.

    Conclusion:

    MBRX stock is enjoying the bullish sentiment in the stock market in response to fast-track designation approval for Annamycin. Management is optimistic to receive early approval for its product in the future. Hence investors should do fundamental as well as technical analysis of MBRX stock before taking any decision.

  • Humanigen, Inc. (HGEN) stock Continues to Gain today: Things you Need to Know

    Humanigen, Inc. (HGEN) stock Continues to Gain today: Things you Need to Know

    Humanigen, Inc. (HGEN) announced positive phase 3 Topline results of lenzilumab,  humanized monoclonal antibody, after which the HGEN stock price saw a surge of 45.42% today’s session to reach $20.34 a share as of this writing. HGEN stock was also green in the previous trading session and at closing, it was up by 1.67% with a $13.99 per share price. Let’s understand more about today’s HGEN news.

    A deep look at Clinical Results.

    Humanigen was performing a phase three clinical trial of lenzilumab for the past couple of months. The study was based on the evaluation of efficacy and safety results of lenzilumab in the hospitalized patients suffering from COVID-19. According to the phase three results, the patients who had received lenzilumab along with steroids or remdesivir were more likely to survive without the use of invasive mechanical ventilation (IMV) as compared to the patients who did not receive the lenzilumab.HGEN was happy to see these results.

    Mayo Clinic was the part of this study and Zelalem Temesgen, MD, who is a professor at Mayo Clinic, was serving as the Principal investigator of this trial. According to him,  lenzilumab proved to be much effective in its results as it significantly reduced the chances of one’s going on a ventilator. Andrew Badley, MD, a professor of Infectious Diseases, showed much excitement about these results. He said that lenzilumab would be an important part of Mayo Clinic in future trials if it gets approval from U.S. Food and Drug Administration.

    Next Goal of Humanigen, Inc.

    After getting exceptional results in phase three clinical trial of lenzilumab, Humanigen’s management is planning to apply for the grant of getting Emergency Use Authorization(EUA)   by the Food and Drug Administration.  Humanigen also sharing these results with different governmental agencies of the U.S as well as authorities of many countries in the globe.

    Financial View of HGEN stock

    On March 10, 2021, Humanigen stock announced its fourth quarter and fiscal year 2020 results according to which HGEN stock recorded the net loss of $89.5 million or $2.42 per share in 2020 as compared to a net loss of $10.3 million or $0.46 per share in 2019. This increase was mainly due to a massive increase in the research and development expenses in 2020. The R&D expenses for 2020 were $72.7 million while these were just $2.6 million in 2019. $67.7 million of cash and cash equivalents were recorded at the end of 2020.

    Conclusion:

    Considering the market sentiment, HGEN stock is in a good position as investors are responding to the news announced by Humanigen, Inc.Positive results of the phase three study would prove to be fruitful for the HGEN stock in the future. Recent earnings report shows that Humanigen has progressed over the year. Hence HGEN stock can be a good bet in the long run.

  • CPI Aerostructures, Inc. (CVU) Stock Rises 33% Today, Let’s Find out Why

    CPI Aerostructures, Inc. (CVU) announced on March 17, 2021, that it has received a follow on order from Lockheed Martin, a security and aerospace company after which the CVUstock became green as CVU stock price pushed by 33.61% to reach $6.52 a share as of this writing. At the previous closing, CVU stock was down by 0.20% with a $4.880 per share price. Let’s deeply dive to understand the bullish sentiment.

    What’s happening?

    CPI Aerostructures, Inc. (CVU) mainly works for the manufacturing of structural aircraft parts for helicopters and fixed-wing aircraft in commercial and defense markets. Today Lockheed Martin awarded a follow-on order to CPI Aerostructures, Inc. (CVU) for the manufacturing of structural assemblies of newly F-16 Block 70/72 aircraft.CVU stock has received many orders in the past from Lockheed Martin but this new order is the biggest one so far making the order book more than double to $17.9 million. Deliveries are expected to occur in 2020 and 2023.

    Past Developments:

    CVU stock on February 18, 2021, reported that it has been awarded $2.7 million in Excelsior Jobs tax credit and $1.05 million Capital Grant for its growth and retain its headquarters in New York State.CVU is expected to invest $5.7 million for its expansion which includes new equipment, infrastructure improvement, and the addition of 85 new full-time jobs.

    On February 16, 2021, CPI Aerostructures had been awarded an $8.7 million purchase order by the U.S Air Force. In connection with a purchase order, it is the responsibility of CVU to ensure the provision of structural modification kits, logistics, program management, and other desired services mentioned in the contract.

    We are not done here yet as CVU also won another order from the Raytheon Missiles & Defense back in January 2021 according to which CVU will manufacture structural assemblies for the former.Deliveries are expected to start within this year.

    Conclusion:

    Follow on order from Lockheed Martin has made the momentum for CVU stock price to rise. Recent development by the CPI Aerostructures points to the growth of the CVU stock in the future. CVUhas succeeded in winning the confidence of Lockheed Martin and expecting to work for LMT in many years to come. Hence investors should keep an eye on this stock.